

Combining an HIV vaccine with immunotherapy may reduce the need for daily medication

September 30 2021, by Sheikh Abdul Rahman, Bhругu Yagnik, Rama Rao Amara



Credit: Pixabay/CC0 Public Domain

[A new combination treatment for HIV](#) can strengthen a patient's immune

response against the virus even after they stop taking traditional medications, according to a study published in the journal *Science Immunology* we co-led at the [Amara Lab at Emory University](#).

People with HIV take a [combination of HIV medications](#) to reduce the amount of virus they have in their body. When taken as prescribed, these medications, collectively called [antiretroviral therapy](#), can reduce the amount of virus in the body to undetectable levels. Antiretroviral therapy must be [taken daily](#) so the virus is less likely to mutate and [become resistant to the drugs](#).

While reducing the amount of virus in the body to undetectable levels means it can [no longer be transmitted](#), however, the most effective [antiretroviral therapy](#) drugs are unable to completely eliminate the virus. This is because HIV hides in [immune-privileged](#) areas of the body, such as certain parts of the lymphoid tissue, that are less accessible to the [immune system](#) to protect them from damage. [Killer T cells](#), which search for and eliminate infected [cells](#), are unable to patrol these [viral reservoirs](#) that harbor HIV.

[Constant exposure](#) to the virus can push killer T cells into a [state of exhaustion](#) in which they don't work as well. Exhausted killer T cells display more of a protein called [PD-1](#), which functions as an "off switch" to its killing activity.

One way to reverse killer T cell exhaustion is to [block the PD-1 off switch](#), but this does not boost the immune system's response to the virus. Conversely, an HIV vaccine can significantly boost immunity against the virus.

So we tested whether [combining these two tactics](#) could enhance HIV infection control. We administered a vaccine for [SIV](#), a close cousin to HIV, with a drug that blocks PD-1 in SIV-infected [rhesus monkeys](#)

treated with antiretroviral therapy.

We found that our approach generated robust anti-viral response in multiple parts of the body, including immune-privileged sites in the [lymph nodes](#), and allowed killer T cells to infiltrate and purge viral reservoirs. Most importantly, the monkeys maintained strong immunity against the virus even after they stopped antiretroviral therapy and significantly improved their survival. None of the seven monkeys in the combination treatment group developed AIDS through our six-month follow-up period, compared with half of the monkeys who received only the vaccine or antiretroviral therapy alone.

Why it matters

Around [38 million people worldwide](#) were living with HIV in 2020. If left untreated, HIV can cripple the immune system and leave the body vulnerable to [normally harmless infections](#).

There are accessibility issues with the treatment that must be diligently taken every day for life. A 2015 study estimated that the lifetime antiretroviral therapy cost for someone who acquires HIV at age 35 is [US\\$358,380](#). And many people don't have access to daily antiretroviral therapy. Around [three-quarters of adults with HIV in sub-Saharan Africa](#) do not reach persistent [viral suppression](#) due to lack of treatment availability.

Finally, even though antiretroviral therapy can thoroughly suppress HIV infection, it does not cure it. There is always a risk that the [virus](#) may mutate to [become resistant to existing drugs](#).

What still isn't known

Completely wiping out HIV from the [body](#) is one way to eliminate the need for daily [antiretroviral](#) therapy. But a more achievable strategy is to put the [infected cells](#) in check.

Currently, only [0.5% of HIV positive individuals](#) are considered "[elite controllers](#)" who are able to suppress infection without medication.

While our study showed a potential pathway to control HIV, it is still in development and not ready for human patients. More research is necessary to understand how viral reservoirs form and why certain cells respond differently to different immunotherapies.

What's next

A single form of [therapy](#) may not result in complete HIV remission. Our team is currently testing other drug combinations to unleash the full potential of the immune system and overcome barriers to a cure.

This article is republished from [The Conversation](#) under a Creative Commons license. Read the [original article](#).

Provided by The Conversation

Citation: Combining an HIV vaccine with immunotherapy may reduce the need for daily medication (2021, September 30) retrieved 8 May 2024 from <https://medicalxpress.com/news/2021-09-combining-hiv-vaccine-immunotherapy-daily.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.